Cargando…
Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report
Apatinib is a novel oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which has been proved by clinical trials to be effective and safe for patients with chemotherapy-refractory gastric cancer. To date, there is no study or case report on apatinib treatment for...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359124/ https://www.ncbi.nlm.nih.gov/pubmed/28352185 http://dx.doi.org/10.2147/OTT.S126471 |
_version_ | 1782516332662620160 |
---|---|
author | Deng, Linghui Wang, Yue Lu, Wenbin Liu, Qian Wu, Jie Jin, Jianhua |
author_facet | Deng, Linghui Wang, Yue Lu, Wenbin Liu, Qian Wu, Jie Jin, Jianhua |
author_sort | Deng, Linghui |
collection | PubMed |
description | Apatinib is a novel oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which has been proved by clinical trials to be effective and safe for patients with chemotherapy-refractory gastric cancer. To date, there is no study or case report on apatinib treatment for patients with ovarian cancer. Here, we present the case of a 50-year-old Chinese woman with advanced ovarian cancer, who received apatinib at a daily dose of 500 mg for 28 days per cycle after failure of fourth-line chemotherapy. Favorable oncologic outcome was achieved in this case after treatment with apatinib. The patient’s progression-free survival is now 11.3 months, and she is taking apatinib and capecitabine as maintenance treatment. The common side effect of apatinib was fatigue; however, the toxicity of apatinib was controllable and tolerable. Thus, apatinib may be an option for chemotherapy-refractory advanced epithelial ovarian cancer, but this still warrants further investigation. |
format | Online Article Text |
id | pubmed-5359124 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-53591242017-03-28 Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report Deng, Linghui Wang, Yue Lu, Wenbin Liu, Qian Wu, Jie Jin, Jianhua Onco Targets Ther Case Report Apatinib is a novel oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which has been proved by clinical trials to be effective and safe for patients with chemotherapy-refractory gastric cancer. To date, there is no study or case report on apatinib treatment for patients with ovarian cancer. Here, we present the case of a 50-year-old Chinese woman with advanced ovarian cancer, who received apatinib at a daily dose of 500 mg for 28 days per cycle after failure of fourth-line chemotherapy. Favorable oncologic outcome was achieved in this case after treatment with apatinib. The patient’s progression-free survival is now 11.3 months, and she is taking apatinib and capecitabine as maintenance treatment. The common side effect of apatinib was fatigue; however, the toxicity of apatinib was controllable and tolerable. Thus, apatinib may be an option for chemotherapy-refractory advanced epithelial ovarian cancer, but this still warrants further investigation. Dove Medical Press 2017-03-13 /pmc/articles/PMC5359124/ /pubmed/28352185 http://dx.doi.org/10.2147/OTT.S126471 Text en © 2017 Deng et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Case Report Deng, Linghui Wang, Yue Lu, Wenbin Liu, Qian Wu, Jie Jin, Jianhua Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report |
title | Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report |
title_full | Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report |
title_fullStr | Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report |
title_full_unstemmed | Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report |
title_short | Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report |
title_sort | apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359124/ https://www.ncbi.nlm.nih.gov/pubmed/28352185 http://dx.doi.org/10.2147/OTT.S126471 |
work_keys_str_mv | AT denglinghui apatinibtreatmentcombinedwithchemotherapyforadvancedepithelialovariancanceracasereport AT wangyue apatinibtreatmentcombinedwithchemotherapyforadvancedepithelialovariancanceracasereport AT luwenbin apatinibtreatmentcombinedwithchemotherapyforadvancedepithelialovariancanceracasereport AT liuqian apatinibtreatmentcombinedwithchemotherapyforadvancedepithelialovariancanceracasereport AT wujie apatinibtreatmentcombinedwithchemotherapyforadvancedepithelialovariancanceracasereport AT jinjianhua apatinibtreatmentcombinedwithchemotherapyforadvancedepithelialovariancanceracasereport |